Please ensure Javascript is enabled for purposes of website accessibility

Why Edwards Lifesciences Gained 13% in March

By Demitri Kalogeropoulos – Apr 5, 2019 at 9:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive clinical trial news lifted shares last month.

What happened

Edwards Lifesciences (EW 1.20%) shares outpaced the market last month by rising 13% compared to a 1.8% uptick in the S&P 500, according to data provided by S&P Global Market Intelligence.

The rally put the stock up more than 20% so far in 2019, versus a 15% rise in the broader market.

Surgeons at work in an operating room.

Image source: Getty Images.

So what

The medical device giant, whose products specialize in treating structural heart disease, got a boost from investors when the company revealed in mid-March that its Sapien 3 transcatheter aortic valve is proving successful over traditional surgeries. Specifically, a randomized trial has found a 46% reduction in death and rehospitalizations one year after patients received the valve replacement as compared to patients undergoing open-heart surgery. Put another way, just 1% of patients faced death or a disabling strong a year into the treatment, compared to 2.9% who underwent surgery.

Now what

Thanks to this positive data, Edwards Lifesciences is optimistic that Sapien 3 will soon be approved for a wider range of patients suffering from severe aortic stenosis. That might help the company improve upon its stable market share position in 2018 in this key industry niche.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.